Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tivozanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 20/20 | 0.98 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 0.98 |
| ▸ | FLT4 known ✓ | P35916 | 4/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 3/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.98 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.98 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.98 |
| ▸ | STK10 | O94804 | 2/20 | 0.98 |
| ▸ | ABL1 | P00519 | 2/20 | 0.98 |
| ▸ | RET | P07949 | 2/20 | 0.98 |
| ▸ | BCR | P11274 | 2/20 | 0.98 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.98 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.98 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.98 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.98 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.98 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.98 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tivozanib SCHEMBL30993908 | 1.00 | KDR (0.98) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL21174286 | 0.99 | KDR (0.97) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL29394095 | 0.99 | KDR (0.97) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL29354604 | 0.99 | KDR (1.00) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL172883 | 0.99 | KDR (1.00) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL29354238 | 0.99 | KDR (1.00) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5214691 | 0.96 | KDR (0.93) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5209537 | 0.96 | KDR (0.93) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5211590 | 0.94 | KDR (0.90) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5545131 | 0.94 | KDR (0.90) | KDRPDGFRAFLT1FLT4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017037220-A1 | ROS1 POSITIVE CANCER TREATMENT | IST AUSTRIA (AT) | 2017-03-09 | — | — | WO | claimed |
| US-20120252829-A1 | TIVOZANIB AND CAPECITABINE COMBINATION THERAPY | AVEO PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | claimed |
| EP-2498606-A1 | TIVOZANIB AND TEMSIROLIMUS IN COMBINATION | Aveo Pharmaceuticals, Inc. (US) | 2012-09-19 | — | — | EP | claimed |
| WO-2011060162-A1 | TIVOZANIB AND TEMSIROLIMUS IN COMBINATION | AVEO PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | claimed |
| US-7166722-B2 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-01-23 | — | — | US | claimed |
| US-11951103-B2 | Pharmaceutical composition | KYOWA KIRIN CO., LTD. (JP) | 2024-04-09 | — | — | US | disclosed |
| WO-2023096651-A1 | METHODS FOR TREATING BILE DUCT CANCERS WITH TIVOZANIB | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-3513809-B9 | MEDICINAL COMPOSITION COMPRISING TIVOZANIB | KYOWA KIRIN CO LTD (JP) | 2022-07-13 | — | — | EP | disclosed |
| EP-4000634-A1 | MEDICINAL COMPOSITION COMPRISING TIVOZANIB | Kyowa Kirin Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
| US-20220000858-A1 | USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER | AVEO PHARMACEUTICALS, INC. | 2022-01-06 | — | — | US | disclosed |
| EP-3876934-A1 | USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER | Aveo Pharmaceuticals, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-10894043-B2 | Pharmaceutical composition | KYOWA KIRIN CO., LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| WO-2017037220-A1 | ROS1 POSITIVE CANCER TREATMENT | IST AUSTRIA (AT) | 2017-03-09 | — | — | WO | disclosed |
| US-20120252829-A1 | TIVOZANIB AND CAPECITABINE COMBINATION THERAPY | AVEO PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| EP-2498606-A1 | TIVOZANIB AND TEMSIROLIMUS IN COMBINATION | Aveo Pharmaceuticals, Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011060162-A1 | TIVOZANIB AND TEMSIROLIMUS IN COMBINATION | AVEO PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| EP-1559715-B1 | N-{2-CHLORO-4-[(6,7-DIMETHOXY-4-QUINOLYL)OXY]PHENYL}-N'-(5-METHYL-3-ISOXAZOLYL)UREA SALT IN CRYSTALLINE FORM | KIRIN BREWERY (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-7166722-B2 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20060052415-A1 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1559715-A1 | N-[2-CHLORO-4-(6,7-DIMETHOXY-4-QUINOLYL)OXY]PHENYL]-N'-(5-METHYL-3-ISOXAZOLYL)UREA SALT IN CRYSTALLINE FORM | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052415-A1 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form | UACA, REN, TPMT | KDR 421/4885FLT1 1068/4885FLT4 242/4885 |
| US-10894043-B2 | Pharmaceutical composition | EGFR, VEGFA, KDR | KDR 3/4885FLT1 4/4885FLT4 5/4885 |
| US-20220000858-A1 | USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER | PBK, PDCD1LG2, CD274 | KDR 119/4885FLT1 678/4885FLT4 258/4885 |
| US-11951103-B2 | Pharmaceutical composition | EGFR, VEGFA, KDR | KDR 3/4885FLT1 4/4885FLT4 5/4885 |
| US-20120252829-A1 | TIVOZANIB AND CAPECITABINE COMBINATION THERAPY | TYMP, TYMS, DPYD | KDR 601/4885FLT1 811/4885FLT4 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.